Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
Status:
Completed
Trial end date:
2021-06-15
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are:
- To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily
(od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial
infarction, stroke, or cardiovascular death in subjects with coronary artery disease
(CAD) or peripheral artery disease (PAD);
- To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the
risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects
with CAD or PAD.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Collaborators:
Hamilton Health Sciences Corporation, Population Health Research Institute Janssen Research & Development, LLC Population Health Research Institute